Social anxiety disorder (SAD), also known as social phobia, is arguably one of the most common mental health problems seen in primary care, only being exceeded by depression; however, it frequently goes unrecognised. It is common that GPs, rather than psychiatrists, face the challenge of making a diagnosis and explaining the treatment options. Evidence suggests that there is a significant need to identify patients with SAD, as it remains under-diagnosed and under-treated. Frequently, patients with SAD present with co-morbid and overlapping anxiety and mood disorders in addition to substance misuse. There are effective treatments for SAD, they include both pharmacotherapy and cognitive behavioural therapy; however, if the condition remains unrecognised there is a strong association with long-term disability and distress. The aim of this article is to increase awareness among GP trainees of this common mental health problem and to shed some light on this disorder and its treatment options.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, fourth edition, Washington, DC: American Psychiatric Association.
2.
BaldwinD.BobesJ.SteinD. J.ScharwaechterI.FaureM. (1999) Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. British Journal of Psychiatry175: 120–126. doi: 10.1192/bjp.175.2.120.
3.
CarriganaM.RandallB. C. (2003) Self-medication in social phobia: A review of the alcohol literature. Addictive Behaviors28(2): 269–284. doi: 10.1016/S0306-4603(01)00235-0.
4.
ConnorK. M.DavidsonJ. R. T.ChurchillL. R.SherwoodA.WeislerR. A.FoaE. (2000) Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale. The British Journal of Psychiatry176(4): 379–386. doi: 10.1192/bjp.176.4.379.
5.
Crosby BudingerM.DrazdowskiT.K.GinsburgG. S. (2013) Anxiety-promoting parenting behaviors: A comparison of anxious parents with and without social anxiety disorder. Child Psychiatry and Human Development44(3): 412–418. doi: 10.1007/s10578-012-0335-9.
6.
CrumR. M.PrattL. A. (2001) Risk of heavy drinking and alcohol use disorders in social phobia: Prospective analysis. American Journal of Psychiatry158(10): 1693–1700. doi: 10.1176/appi.ajp.158.10.1693.
7.
Davidson, J. R. T., Miner, C. M., De Veaugh-Geiss, J., Tupler, L. A., Colket, J. T., & Potts, N. L. S. (1997). The brief social phobia scale: A psychometric evaluation. Psychological Medicine, 27(1), 161–166. doi: 10.1017/S0033291796004217.
8.
Fenn, K., & Byrne, M. (2013). The key principles of cognitive behavioural therapy. InnovAiT, 6(9), 579–585.
9.
Fedoroff, I. C., & Taylor, S. (2001). Psychological and pharmacological treatments of social phobia: A meta-analysis. Journal of Clinical Psychopharmacology, 21(3), 311–324. doi: 10.1097/00004714-200106000-00011.
10.
EnglandE.LesterH. (2007) Implementing the role of the primary care mental health worker: A qualitative study. British Journal of General Practice57(536): 204–211.
11.
FurmarkT.CarlbringP.HedmanE.SonnensteinA.ClevbergerP.BohmanB.ErikssonA. (2009) Guided and unguided self-help for social anxiety disorder: Randomised controlled trial. The British Journal of Psychiatry195(5): 440–447. doi: 10.1192/bjp.bp.108.060996.
12.
GelderM.AndreasenN.Lopez-IborJ.GeddesJ. (2009) New Oxford textbook of psychiatry, Oxford, UK: Oxford University Press.
13.
GrossR.OlfsonM.GameroffM. J.SheaS.FederA.LantiguaR.WeissmanM. M. (2005) Social anxiety disorder in primary care. General Hospital Psychiatry27(3): 161–168. doi: 10.1016/j.genhosppsych.2005.01.006.
14.
HayesJ. F. (2011) Generalized anxiety disorder. InnovAiT4(12): 685–690. doi: 10.1093/innovait/inr074.
15.
KasperS.DanJ.Stein, LoftH.NilR. (2005) Escitalopram in the treatment of social anxiety disorder. The British Journal of Psychiatry186(3): 222–226. doi: 10.1192/bjp.186.3.222.
16.
Kessler, R. C., Berglund, P., Demler, O., et al. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 593–602.
17.
LaderM.StenderK.BürgerV.NilR. (2004) Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study. Depression and Anxiety19(4): 241–248. doi: 10.1002/da.20014.
18.
LeichsenringF.SalzeS.BeutelM.HerpertzS.HillerW.HoyerJ.NoltingP. (2013) Psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: A multicenter randomized controlled trial. The American Journal of Psychiatry170(7): 759–767. doi: 10.1176/appi.ajp.2013.12081125.
19.
LiebowitzM. R.GelenbergA. J.MunjackD. (2005) Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry62(2): 190–198. doi: 10.1001/archpsyc.62.2.190.
20.
Liebowitz, M. R., Rytwinski, N. R., Stein, M. B., & Shadha Cissell, M. S. W. (2009). Screening for social anxiety disorder with the self-report version of the Liebowitz Social Anxiety Scale. Depression and Anxiety, 26(1), 34–38. doi: 10.1002/da.20503.
21.
Marks, I. M., & Mathews, A. M. (1979). Brief standard self-rating for phobic patients. Behavior Research and Therapy, 17, 263–267.
OlfsonM.GuardinoM.StrueningB.SchneierF.HellmanF.KleinD. (2000) Barriers to the treatment of social anxiety. American Journal of Psychiatry157(4): 521–527. doi: 10.1176/appi.ajp.157.4.521.
25.
PillingS.Mayo-WilsonE.MavranezouliI.KewK.TaylorC.ClarkD. (2013) Recognition, assessment and treatment of social anxiety disorder: Summary of NICE guidance. BMJ346: f2541, doi: 10.1136/bmj.f2541.
SteinG.WilkinsonG. (2007) Seminars in general adult psychiatry, London, UK: Royal College of Psychiatrists, pp. 352–360.
29.
SteinM. B.LiebowitzM. R.LydiardR. B.PittsC. D.BushnellW.GergelI. (1998) Paroxetine treatment of generalized social phobia: A randomized controlled trial. The Journal of the American Medical Association280(8): 708–713. doi: 10.1097/00004714-199606000-00005.
Turner, S. M., Beidel, D. C., Dancu, C. V., & Stanley, M. A. (1989). An empirically derived inventory to measure social fears and anxiety: The Social Phobia and Anxiety Inventory. A Journal of Consulting and Clinical Psychology, 1(1), 35–40. doi: 10.1037/1040-3590.1.1.35.
32.
Van AmeringenM. A.LaneR. M.WalkerJ. R.BowenR. C.ChokkaP. R.GoldnerE. M.SwinsonR. P. (2001) Sertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study. American Journal of Psychiatry158(2): 275–281. doi: 10.1176/appi.ajp.158.2.275.
33.
VealeD. (2003) Treatment of social phobia. Advances in Psychiatric Treatment9(4): 258–264. doi: 10.1192/apt.9.4.258.
34.
WadeA.LemmingO. M.HedegaardK. B. (2002) Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. International Clinical Psychopharmacology17(3): 95–102. doi: 10.1097/00004850-200205000-00001.
35.
WeillerE.BisserbeJ. C.BoyerP.LepineJ. P.LecrubieY. (1996) Social phobia in general health care: An unrecognised undertreated disabling disorder. The British Journal of Psychiatry168(2): 169–174. doi: 10.1192/bjp.168.2.169.
36.
WeistockL. S. (1999) Gender differences in the presentation and management of social anxiety disorder. Journal of Clinical Psychiatry60(9): 9–13.
